Navigation Links
Abbott's TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets

Post-hoc analysis of two large clinical trials showed combination therapy helped more patients reach combined targets for HDL, triglycerides and LDL than the pre-determined therapy alone

NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- Abbott's (NYSE: ABT) TRILIPIX (R) (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium achieved individual and combined lipid targets in patients with mixed dyslipidemia and type 2 diabetes. In these patients, the combination of TRILIPIX and rosuvastatin helped up to three times more patients simultaneously reach all three key lipid targets - HDL, triglycerides and LDL - than the pre-determined monotherapy. Results from this post-hoc analysis were presented today at the American Diabetes Association's 2009 Scientific Sessions.

TRILIPIX is a prescription medicine used along with diet to lower triglycerides and LDL (bad) cholesterol, and increase HDL (good) cholesterol. TRILIPIX is also used along with diet to lower triglycerides and increase HDL cholesterol in people who are at high risk of heart disease and are taking a statin medicine to control their LDL cholesterol. TRILIPIX has not been shown to prevent heart attacks or stroke more than a statin alone.

Dyslipidemia affects millions of Americans living with diabetes. These patients often have mixed dyslipidemia, a combination of two or more lipid problems including low HDL, high triglycerides and high LDL.

"Because diabetes is a risk factor for heart disease, it is particularly important that patients with diabetes and mixed dyslipidemia manage all three key lipid parameters," said Robert Rosenson, M.D., State University of New York, Brooklyn, New York. "The results of this analysis are promising for combination therapy with TRILIPIX and rosuvastatin."

TRILIPIX is the first and only fibrate to be approved for use in combination with a statin. In certain patients, treatment guidelines recommend the combination of a fibrate with a statin to improve lipid levels.

TRILIPIX should not be taken by people with liver, gallbladder, or severe kidney disease or by nursing mothers. Blood tests should be performed before and during treatment with TRILIPIX to check for liver problems. A healthcare provider should be contacted if serious side effects such as unexplained muscle pain, tenderness, or weakness develop. The risk of these side effects may be higher when TRILIPIX is used with a statin.

About the Phase 3 Clinical Trials

A total of 2,197 patients with mixed dyslipidemia were enrolled in two phase 3 clinical studies evaluating TRILIPIX in combination with rosuvastatin 5 mg, 10 mg, or 20 mg compared to either TRILIPIX alone or rosuvastatin alone. Both studies met their primary endpoints, with combination therapy significantly improving HDL and triglycerides compared to rosuvastatin alone, and significantly improving LDL compared to TRILIPIX alone. The combination of TRILIPIX with the highest dose of rosuvastatin (40 mg) has not been studied. These studies are part of the largest clinical program to date designed to evaluate the safety and efficacy of a fibrate in combination with statins.

About the Post Hoc Analysis

This post-hoc analysis of two 12-week, randomized phase 3 studies of patients with mixed dyslipidemia examined a subgroup of 480 patients with type 2 diabetes. These patients were required to have an LDL greater than or equal to 130 mg/dL, triglycerides greater than or equal to 150 mg/dL and HDL less than 40 mg/dL for men and less than 50 mg/dL for women to be included in the study.

The analysis compared the proportion of patients reaching American Diabetes Association (ADA) lipid targets who received TRILIPIX in combination with rosuvastatin to those who received the corresponding dose of rosuvastatin alone, the pre-determined monotherapy. The ADA lipid targets included LDL less than 100 mg/dL, triglycerides less than 150 mg/dL and HDL greater than 40 mg/dL for men and greater than 50 mg/dL for women.

About the Study Results

More patients simultaneously achieved all three ADA lipid targets for HDL, triglycerides and LDL when receiving TRILIPIX in combination with rosuvastatin 10 mg (28.3 percent vs. 8.3 percent; p=0.012) or 20 mg (19.1 percent vs. 5.9 percent; p= 0.045) compared to rosuvastatin 10 mg or 20 mg alone, respectively. Additionally, TRILIPIX in combination with rosuvastatin 5 mg resulted in 21.7 percent of patients achieving all three ADA lipid targets simultaneously compared to 12.1 percent of patients receiving rosuvastatin 5 mg alone (p=0.137). TRILIPIX monotherapy resulted in 4.3 percent of patients obtaining simultaneous achievement of these goals.

"The clinical program continues to generate important data supporting the use of TRILIPIX in combination with rosuvastatin therapy in high risk patient populations," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development, Abbott.

TRILIPIX Clinical Development Program

The TRILIPIX clinical program studied 3,458 patients with mixed dyslipidemia in four 12-week controlled studies where patients received TRILIPIX alone, TRILIPIX in combination with one of the three most commonly prescribed statins (atorvastatin, simvastatin or rosuvastatin) or statin alone. The clinical program also included a 52-week, long-term, open-label extension study.

Important Safety Information About TRILIPIX

TRILIPIX should not be taken by people with liver, gallbladder, or severe kidney disease, nursing mothers, or those allergic to any product ingredient. Unexplained muscle pain, tenderness, or weakness, particularly when occurring with tiredness and fever, may be a sign of a serious side effect and should be reported to a healthcare provider right away. Rarely, muscle-related problems can cause kidney damage and can be fatal. The risk of these side effects may be increased when TRILIPIX is used with a statin. Patients should tell their healthcare provider about all the medicines they take. Blood tests should be performed before and during treatment with TRILIPIX to check for liver or kidney problems.

Patients should contact their healthcare provider if they experience abdominal pain, nausea, or vomiting while taking TRILIPIX. These may be signs of inflammation of the gallbladder or pancreas. Women who are pregnant should not take statins and should talk with their healthcare provider about TRILIPIX if they are pregnant or may become pregnant.

The most common side effects with TRILIPIX include headache, heartburn, nausea, muscle aches, and increases in muscle or liver enzymes that are measured by blood tests. Full Prescribing Information is available at Visit or call Abbott Medical Information at 1-800-633-9110 for more information about TRILIPIX.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
2. (Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
3. Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
4. QLT announces positive results from the evaluation of Visudyne(R) combination therapy
5. 2-drug combination appears safe and active in metastatic kidney cancer
6. New treatment combination proves safe for head and neck cancer patients
7. Study shows drug combination improves outcome for advanced non-small cell lung cancer
8. Chemotherapy combination outcomes differ for aged, younger colon cancer patients
9. Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
10. Transplant Surgery and Identity: A Discussion Among Pioneers with Unusual Combinations of Interests, Skills and Talents
11. Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: